Bioreduction of idarubicin and formation of ROS responsible for DNA cleavage by NADPH-cytochrome P450 reductase and its potential role in the antitumor effect

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 11, Issue 4, 2008, Pages 68-82

  Çelik, Haydar ^a,b   Arinç, Emel ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DNA; IDARUBICIN; MITOMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

ANIMAL; ARTICLE; CHEMISTRY; DNA CLEAVAGE; ENZYMOLOGY; HUMAN; ISOLATION AND PURIFICATION; LUNG; METABOLISM; MICROSOME; OXIDATION REDUCTION REACTION; SHEEP;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DNA; DNA CLEAVAGE; HUMANS; IDARUBICIN; LUNG; MICROSOMES; MITOMYCIN; NADP; NADPH-FERRIHEMOPROTEIN REDUCTASE; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; SHEEP;

EID: 65249112738     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3s88w     Document Type: Article

References (36)

1. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., Gianni, L., Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev, 56:185-229, 2004.
2. Doroshow, J.H., Anthracyclines and Anthracenediones, in: Chabner BA: Longo DL (eds), Cancer Chemotherapy and Biotherapy: Principles and Practices. Lippincott Williams and Wilkins, Philadelphia, PA, pp 415-450, 2006.
3. Powis, G., Metabolism and reactions of quinoid anticancer agents. Pharmacol Ther, 35:57-162, 1987.
4. Borchmann, P., Hübel, K., Schnell, R., Engert, A., Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther, 35:80-83, 1997.
5. Crivellari, D., Lombardi, D., Spazzapan, S., Veronesi, A., Toffoli, G., New oral drugs in older patients: a review of idarubicin in elderly patients. Crit Rev Oncol Hematol, 49:153-163, 2004.
6. Goebel, M., Oral idarubicin - an anthracycline derivative with unique properties. Ann Hematol, 66:33-43, 1993.
7. Gewirtz, D.A., A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol, 57:727-741, 1999.
8. Sinha, B.K., Free radicals in antitumor drug pharmacology. Chem Biol Interact, 69:293-317, 1989.
9. Powis, G., Free radical formation by antitumor quinones. Free Radic Biol Med, 6:63-101, 1989.
10. Taatjes, D.J., Gaudiano, G., Resign, K., Koch, T.H., Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J Med Chem, 40:1276-1286, 1997.
11. Kappus, H., Overview of enzyme systems involved in bioreduction of drugs and in redox cycling. Biochem Pharmacol, 35:1-6, 1986.
12. Fisher, G.R., Gutierrez, P.L., Free radical formation and DNA strand breakage during metabolism of diaziquone by NAD(P)H quinone-acceptor oxidoreductase (DTdiaphorase) and NADPH cytochrome c reductase. Free Radic Biol Med, 11:597-607, 1991.
13. Shen, T., Hollenberg, P.F., The mechanism of stimulation of NADPH oxidation during the mechanism-based inactivation of cytochrome P450 2B1 by N-methylcarbazole: redox cycling and DNA scission. Chem Res Toxicol 7:231-238, 1994.
14. Kumagai, Y., Tsurutani, Y., Shinyashiki, M., Homma-Takeda, S., Nakai, Y., Yoshikawa, T., Shimojo, N., Bioactivation of lapachol responsible for DNA scission by NADPHcytochrome P450 reductase. Environ Toxicol Pharmacol, 3:245-250, 1997.
15. Garner, A.P., Paine, M.J.I., Rodriguez-Crespo, I., Chinje, E.C., Ortiz De Montellano, P., Stratford, I.J., Tew, D.G., Wolf, C.R., Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res, 59:1929-1934, 1999.
16. Çelik, H., Arinç, E., Bioactivation of mitomycin C responsible for formation of "ROS" and DNA scission by lung cytochrome P450 reductase. FEBS J, 273(Suppl. 1):160, 2006.
17. Çelik, H., Arinç, E., Comparison of the in vitro DNA-damaging potential of the two anticancer drugs idarubicin and mitomycin C in the presence of NADPH-cytochrome P450 reductase. Drug Metab Rev, 38 (Suppl. 1):185-186, 2006.
18. Adali, O., Arinç, E., Electrophoretic, spectral, catalytic and immunochemical properties of highly purified cytochrome P-450 from sheep lung. Int J Biochem, 22:1433-1444, 1990.
19. Işcan, M.Y., Arinç, E., Comparison of highly purified sheep liver and lung NADPHcytochrome P-450 reductases by the analysis of kinetic and catalytic properties. Int J Biochem, 20:1189-1196, 1988.
20. Sen, A., Arinç, E., Purification and characterization of cytochrome P450 reductase from liver microsomes of feral leaping mullet (Liza saliens). J Biochem Mol Toxicol, 12:103-113, 1998.
21. Arinç, E., Çelik, H., Biochemical characteristics of purified beef liver NADPHcytochrome P450 reductase. J Biochem Mol Toxicol, 16:286-297, 2002.
22. Laemmli, U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227:680-685, 1970.
23. Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J., Protein measurement with the Folin phenol reagent. J Biol Chem, 193:265-275, 1951.
24. Masters, B.S.S., Williams, C.H., Kamin, H., The preparation and properties of microsomal TPNH-cytochrome c reductase from pig liver. Methods Enzymol, 10:565-573, 1967.
25. Yonetani, T., Studies on cytochrome c peroxidase. II. Stoichiometry between enzyme, H2O2 and ferrocytochrome c and enzymic determination of extinction coefficients of cytochrome c. J Biol Chem, 240:4509-4514, 1965.
26. 2 on plasmid DNA. Mutat Res, 466:1-7, 2000.
27. Seow, H.A., Penketh, P.G., Baumann, R.P., Sartorelli, A.C., Bioactivation and resistance to mitomycin C. Methods Enzymol, 382:221-233, 2004.
28. Pawlowska, J., Tarasiuk, J., Wolf, C.R., Paine, M.J.I., Borowski, E., Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase and xanthine oxidase. Oncol Res, 13:245-252, 2003.
29. Tarasiuk, J., Garnier-Suillerot, A., Stefanska, B., Borowski, E., The essential role of anthraquinones as substrates for NADH dehydrogenases in their redox cycling activity. Anticancer Drug Des, 7:329-340, 1992.
30. Brawn, K., Fridovich, I., DNA strand scission by enzymatically generated oxygen radicals. Arch Biochem Biophys, 206:414-419, 1981.
31. Kovacic, P., Osuna, J.A. Jr., Mechanisms of anti-cancer agents: emphasis on oxidative stress and electron transfer. Curr Pharm Des, 6:277-309, 2000.
32. Lu, A.Y.H., NADPH-Dependent Cytochrome P450 Reductase, in: Arinç E: Schenkman JB: Hodgson E (eds), Molecular Aspects of Monooxygenases and Bioactivation of Toxic Compounds. Plenum Press, New York, NY, pp 135-147, 1991.
33. Shen, A., Kasper, C.B., Protein and Gene Structure and Regulation of NADPHCytochrome P450 Reductase, in: Schenkman JB: Greim H (eds), Handbook of Experimental Pharmacology. Springer-Verlag Press, New York, NY, pp 35-59, 1993.
34. Gutierrez, A., Grunau, A., Paine, M., Munro, A.W., Wolf, C.R., Roberts, G.C., Scrutton, N.S., Electron transfer in human cytochrome P450 reductase. Biochem Soc Trans, 31:497-501, 2003.
35. Cowen, R.L., Garside, E.J., Fitzpatrick, B., Papadopoulou, M.V., Williams, K.J., Gene therapy approaches to enhance bioreductive drug treatment. Br J Rad, 81:S45-S56, 2008.
36. Altaner C., Prodrug cancer gene therapy. Cancer Letters, 270:191-201, 2008.